Clinical trial
Erlotinib Prevention of Oral Cancer (EPOC)
NCT00402779 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00402779 |
|---|---|
| Title | Erlotinib Prevention of Oral Cancer (EPOC) |
| Official title | Erlotinib Prevention of Oral Cancer (EPOC) |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH Astellas Pharma US, Inc. Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Oral Cancer |
| Intervention type | Drug |
| Interventions | Erlotinib, Placebo |
| Enrollment | 303 |
| Start date | Nov 3, 2006 |
| Primary completion | Jun 4, 2018 |
| Completion | Jun 4, 2018 |
| First posted | Nov 22, 2006 |
| Last update posted | Apr 21, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: